Corella Resources Ltd (CR9)

Snapshot

CR9's Principal Activity is the reviewing potential acquisition opportunities.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Mr Anthony (Tony) Stephen Cormack	Non-Executive Director	Apr 2021	Mr Anthony (Tony) Stephen Cormack Non-Executive Director --
Mr Philip Re	Non-Executive Director	Apr 2021	Mr Philip Re Non-Executive Director --
Mr Peter Woods	Non-Executive Director	Apr 2021	Mr Peter Woods Non-Executive Director --
Mr Daniel Coletta	Joint Company Secretary	Dec 2020	Mr Daniel Coletta Joint Company Secretary Mr Coletta has experience in accounting and compliance.
Mr Derek Hall	Company Secretary	Dec 2019	Mr Derek Hall Company Secretary Mr Hall is a finance and compliance specialist in the listed space. Mr Hall has commercial experience identifying key business drivers and bringing cost control and process improvement into sharp focus. Mr Hall has been involved as a Chief Financial Officer and Company Secretary for a number of publicly listed and unlisted companies involving transactions in technology, mining, oil and gas and construction.
Dr Paul Bello	Joint Company Secretary	Oct 2008
Mr Giorgio Reggiani	Company Secretary	Feb 2008
Mr Harry Karelis	Non-Executive Director	N/A	Mr Harry Karelis Non-Executive Director --
Mr Leslie Harold Webb	Non-Executive Director	N/A	Mr Leslie Harold Webb Non-Executive Director Mr Webb was establishing ITV Consulting Pty Limited, a corporate advisory and investment consulting business. He is also a Non-executive Director of pharmaceutical company Generic Health Limited and health insurance company iSelect. He previously sat on the Board of the ASX listed Gradipore Ltd (now Life Therapeutics).
Mr David Dodd	Chairman	N/A	Mr David Dodd Chairman Mr Dodd's experience includes management and corporate development experience in the life sciences industry. Prior to joining the Stem Cell Sciences, he was President, Chief Executive Officer and Director of NASDAQ quoted Serologicals Corporation until it was acquired by Millipore Corporation on 14 July 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals Inc. and as a member of the Management Board for the Pharmaceutical Sector for Solvay SA. He was also Chairman of the Board of Unimed Pharmaceuticals Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. He was awarded the 2005 GBP Biomedical Industry Growth Award for his efforts in promoting Georgia's life sciences industry. In addition, he received the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group, in recognition of his ongoing leadership in fostering business relationships between the USA and the United Kingdom. David is also currently serving on the board of directors of Stheno Corporation, a private life sciences instrument company, as Non-executive Director; as Chairman of the Board of the American Foundation for Suicide Prevention; and, as Immediate Past-Chair, the Georgia Biomedical Partnership, and the biotechnology trade association in the State of Georgia. He was appointed President, CEO and Chairman of Bioreliance Corporation on 3 December 2007.
Dr Peter Mountford	Non-Executive Director	N/A	Dr Peter Mountford Non-Executive Director Dr Mountford is currently a Director of all the companies within Stem Cell Sciences, as well as of the private company Secure Sciences Pty Ltd.
Dr Michael (Mike) Dexter	Non-Executive Director	N/A	Dr Michael (Mike) Dexter Non-Executive Director Dr Dexter spent the five years prior to joining Stem Cell Sciences as Director (Chief Executive Officer) of The Wellcome Trust. During his time at The Wellcome Trust, he oversaw one of the biggest advances in biomedical research when it was announced that the human genome had been sequenced - giving scientists a detailed map of the body's make-up for the first time. Prior to joining The Wellcome Trust, he was Director of Research at the Paterson Institute for Cancer Research, Christie Hospital, NHS Trust, Manchester. He is a Fellow of the Royal Society (London), was appointed Professor of Experimental Oncology at the University of Manchester and is an honorary Fellow of the Royal College of Physicians and a founding fellow of the Academy of Medical Sciences. He is currently Chairman of the International Centre for Life, Newcastle, and the Cockcroft Institute for Accelerator Sciences in Daresbury, Cheshire. He was previously a Director of Catalyst Biomedica Ltd, the translational business arm of The Wellcome Trust. He has over 360 publications on his scientific work.
Dr Alastair James Riddell	Chief Executive Officer	N/A	Dr Alastair James Riddell Chief Executive Officer Dr Riddell has more than 24 years experience in this industry. He has spent time at Board level building companies, raising money and negotiating corporate deals. From 2006 to 2007, he held the position of Non-executive Chairman at Surface Therapeutics prior to its sale to Serentis in September 2007. From 2005, he was Chief Executive Officer of Paradigm Therapeutics where he achieved a trade sale to Takeda Pharmaceutical Corporation in March 2007. Prior to Paradigm, he was Chief Executive Officer of Pharmagene for seven years, during which time he listed the company on the main market of the London Stock Exchange. He has also held senior positions with Celltech, Centocor and Amersham International in clinical development before moving to sales and marketing. He began his professional career as a medical doctor with six years, experience in a variety of hospital specialties and in general practice. He is an active Board member of the BIA, a position he has held from 2000 to 2006 and recently re-elected to serve for the 2008 term. In November 2007, he joined the Board of Sareum Holdings plc as Non-executive Director.
Paul Bello	Joint Company Secretary	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
20/04/21	Warren Barry	Issued	3,627,753	$0.003	$10,883	Director remuneration
20/04/21	Warren Barry	Issued	581,402	$0.02	$11,628	Director remuneration
20/04/21	Terence (Terry) Butler	Issued	1,976,525	$0.02	$39,530	Director remuneration
20/04/21	Terence (Terry) Butler	Issued	5,525,918	$0.003	$16,577	Director remuneration
20/04/21	Derek Hall	Issued	2,674,086	$0.003	$8,022	Director remuneration
20/04/21	Derek Hall	Issued	2,674,086	$0.02	$53,481	Director remuneration
01/04/21	Warren Barry	Transfer	48,427,031	$0.003	$145,281	Off-market transfer
01/04/21	Warren Barry	Transfer	48,427,031	$0.003	$145,281	Off-market transfer

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Daniel Coletta	23/04/2021	0	N/A	N/A	N/A
Peter Woods	23/04/2021	N/A	22,000,000	4,500,000	N/A
Philip Re	23/04/2021	N/A	7,000,000	4,500,000	N/A
Anthony (Tony) Cormack	23/04/2021	13,909,091	N/A	N/A	N/A
Derek Hall	23/04/2021	0	2,674,086	2,674,086	N/A
Alastair Riddell	23/05/2008	N/A	N/A	1,005,484	N/A
Peter Mountford	20/03/2008	N/A	3,368,633	N/A	N/A
David Dodd	09/10/2006	65,420	N/A	N/A	N/A
Michael (Mike) Dexter	N/A	N/A	N/A	N/A	N/A
Leslie Webb	N/A	N/A	N/A	N/A	N/A
Harry Karelis	N/A	N/A	N/A	N/A	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Spruson Corporation Pty Ltd <Booyah Family A/C>	71,935,828	7.10%
Terence Butler & Rosemary Butler <Butler Super Fund A/C>	59,437,876	5.86%
BTR Holdings Pty Ltd <Mushy One A/C>	56,488,421	5.57%
Rimoyne Pty Ltd	50,000,000	4.93%
Barry Consulting Pty Ltd <Barry Family A/C>	48,427,031	4.78%
Ligurian Holdings Pty Ltd	47,500,229	4.69%
Marindo Nominees Pty Ltd	41,250,000	4.07%
Mingoola Pty Ltd	37,543,051	3.70%
On Time Taxis Pty Ltd	25,000,000	2.47%
Crossbay Pty Ltd	25,000,000	2.47%
Philip Re & Leah Re <Re Family Super Fund A/C>	25,000,000	2.47%
Blueseas Investments Pty Ltd <Asean Super Fund A/C>	22,533,182	2.22%
Luigi Baccini & & Loredana Baccini <Baccini Super Fund A/C>	20,000,000	1.97%
Chembank Pty Limited <Cabac Super Fund A/C>	20,000,000	1.97%
MSJ Capital Pty Limited <Msj Family A/C>	19,960,799	1.97%
Traditional Securities Group Pty Ltd <Lpr Family A/C>	16,000,229	1.58%
MSJ Capital Pty Limited <The Harrison S/F A/C>	15,414,746	1.52%
Tyson Kane Smith	15,000,000	1.48%
Mandevilla Pty Ltd	14,050,000	1.39%
Medidew Pty Ltd <The Medidew A/C>	12,879,317	1.27%
Warren Barry & Sonia Barry <Barry Family Superfund A/C>	12,500,000	1.23%
Capretti Investments Pty Ltd <Castello A/C>	11,786,696	1.16%
Ant (Act) Nominees Pty Limited <Butler Family A/C>	11,550,000	1.14%
Perizia Investments Pty Ltd	11,550,000	1.14%
Stephen Harrison	11,550,000	1.14%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

CR9 Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.